{"id":36338,"date":"2025-08-27T12:23:37","date_gmt":"2025-08-27T12:23:37","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/24-7-market-news-lixte-showcases-lb-100-at-first-global-conference-on-oncogenic-signaling-activation-as-cancer-therapy\/"},"modified":"2025-08-27T12:23:37","modified_gmt":"2025-08-27T12:23:37","slug":"24-7-market-news-lixte-showcases-lb-100-at-first-global-conference-on-oncogenic-signaling-activation-as-cancer-therapy","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/24-7-market-news-lixte-showcases-lb-100-at-first-global-conference-on-oncogenic-signaling-activation-as-cancer-therapy\/","title":{"rendered":"24\/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy"},"content":{"rendered":"
\n

DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) — 247marketnews.com<\/strong>, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, highlights the publication of a new manuscript in Trends in Cancer<\/em> (July 2025, Vol. 11, No. 7, https:\/\/doi.org\/10.1016\/j.trecan.2025.04.009<\/a>) describing the first international conference on activation of oncogenic signaling as a cancer treatment strategy.<\/p>\n

The landmark meeting was co-sponsored by LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) and co-organized by Professor Rene Bernards, and board member of LIXTE. At the conference, compelling new data was presented showing that LIXTE\u2019s lead compound LB-100 can mediate activation of oncogenic signaling, a process that proves toxic to cancer cells.<\/p>\n

A Paradigm Shift: Oncogenic Signaling as Therapy<\/strong><\/p>\n

Traditional cancer therapies have long focused on inhibiting oncogenic pathways. This meeting explored the counterintuitive strategy of activating these same pathways to push cancer cells beyond survival limits.<\/p>\n

LB-100, a first-in-class PP2A inhibitor, exemplifies this novel approach. By inhibiting PP2A, LB-100 removes a cellular \u201coff switch,\u201d triggering uncontrolled signaling activity in cancer cells. This \u201clethal activation\u201d drives cells into self-destruction, while also generating abnormal proteins (neoantigens) that make tumors more visible to immune attack.<\/p>\n

LB-100: Expanding Validation Across Platforms<\/strong><\/p>\n

The conference reinforced the growing recognition of PP2A inhibition as a new therapeutic frontier. Presentations demonstrated:<\/p>\n